# Rigel Pharmaceuticals Inc: financial statements, quarterly

RIGL · Nasdaq · CIK 1034842 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rigl.md) · [Financials](/companies/rigl/financials.md) · [Filings](/companies/rigl/filings.md) · [Insiders](/companies/rigl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rigl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [28.1](/filings/0001558370-24-014862.md) | [35.8 d](/filings/0001034842-26-000015.md) | [29.5](/filings/0001558370-25-006493.md) | [36.8](/filings/0001558370-25-010281.md) | [55.3](/filings/0001104659-25-106268.md) | [57.6 d](/filings/0001034842-26-000015.md) | [53.3](/filings/0001034842-26-000032.md) | [102](/filings/0001034842-26-000052.md) | [69.5](/filings/0001104659-25-106268.md) | [69.8 d](/filings/0001034842-26-000015.md) | [58.8](/filings/0001034842-26-000032.md) | [78.7](/filings/0001034842-26-000052.md) |
| Cost of revenue | $m | [1.3](/filings/0001558370-24-014862.md) | [3.8 d](/filings/0001034842-26-000015.md) | [2.0](/filings/0001558370-25-006493.md) | [2.8](/filings/0001558370-25-010281.md) | [8.0](/filings/0001104659-25-106268.md) | [5.8 d](/filings/0001034842-26-000015.md) | [4.4](/filings/0001034842-26-000032.md) | [4.5](/filings/0001034842-26-000052.md) | [4.8](/filings/0001104659-25-106268.md) | [6.0 d](/filings/0001034842-26-000015.md) | [4.6](/filings/0001034842-26-000032.md) | [8.5](/filings/0001034842-26-000052.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | [8.4](/filings/0001034842-26-000032.md) | [6.8](/filings/0001034842-26-000052.md) | not reported | not reported | [11.7](/filings/0001034842-26-000032.md) | [14.0](/filings/0001034842-26-000052.md) |
| Selling, general and administrative | $m | [24.9](/filings/0001558370-24-014862.md) | [26.9 d](/filings/0001034842-26-000015.md) | [28.4](/filings/0001558370-25-006493.md) | [28.0](/filings/0001558370-25-010281.md) | [27.0](/filings/0001104659-25-106268.md) | [29.5 d](/filings/0001034842-26-000015.md) | [27.7](/filings/0001034842-26-000032.md) | [29.3](/filings/0001034842-26-000052.md) | [28.9](/filings/0001104659-25-106268.md) | [30.0 d](/filings/0001034842-26-000015.md) | [30.7](/filings/0001034842-26-000032.md) | [32.6](/filings/0001034842-26-000052.md) |
| Operating income | $m | [(4.5)](/filings/0001558370-24-014862.md) | [2.0 d](/filings/0001034842-26-000015.md) | [(7.0)](/filings/0001558370-25-006493.md) | [0.4](/filings/0001558370-25-010281.md) | [14.1](/filings/0001104659-25-106268.md) | [16.7 d](/filings/0001034842-26-000015.md) | [12.8](/filings/0001034842-26-000032.md) | [61.1](/filings/0001034842-26-000052.md) | [28.4](/filings/0001104659-25-106268.md) | [23.2 d](/filings/0001034842-26-000015.md) | [11.9](/filings/0001034842-26-000032.md) | [23.6](/filings/0001034842-26-000052.md) |
| Interest expense | $m | [1.9](/filings/0001558370-24-014862.md) | [1.9 d](/filings/0001558370-25-002169.md) | [1.9](/filings/0001558370-25-006493.md) | [2.0](/filings/0001558370-25-010281.md) | [2.1](/filings/0001104659-25-106268.md) | [2.0 d](/filings/0001558370-25-002169.md) | [1.9](/filings/0001558370-25-006493.md) | [1.9](/filings/0001558370-25-010281.md) | [1.9](/filings/0001104659-25-106268.md) | [1.7 d](/filings/0001034842-26-000015.md) | [1.4](/filings/0001034842-26-000032.md) | [0.8](/filings/0001034842-26-000052.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001558370-25-006493.md) | [0.0](/filings/0001558370-25-010281.md) | [0.0](/filings/0001104659-25-106268.md) | [0.9 d](/filings/0001034842-26-000015.md) | [0.1](/filings/0001034842-26-000032.md) | [0.4](/filings/0001034842-26-000052.md) | [(0.3)](/filings/0001104659-25-106268.md) | [(245) d](/filings/0001034842-26-000015.md) | [3.0](/filings/0001034842-26-000032.md) | [6.3](/filings/0001034842-26-000052.md) |
| Net income | $m | [(5.7)](/filings/0001558370-24-014862.md) | [0.7 d](/filings/0001034842-26-000015.md) | [(8.2)](/filings/0001558370-25-006493.md) | [(1.0)](/filings/0001558370-25-010281.md) | [12.4](/filings/0001104659-25-106268.md) | [14.3 d](/filings/0001034842-26-000015.md) | [11.4](/filings/0001034842-26-000052.md) | [59.6](/filings/0001034842-26-000052.md) | [27.9](/filings/0001104659-25-106268.md) | [268 d](/filings/0001034842-26-000015.md) | [8.7](/filings/0001034842-26-000052.md) | [17.3](/filings/0001034842-26-000052.md) |
| Diluted EPS | $ per share | [(0.33)](/filings/0001558370-24-014862.md) | not reported | [(0.47)](/filings/0001558370-25-006493.md) | [(0.06)](/filings/0001558370-25-010281.md) | [0.70](/filings/0001104659-25-106268.md) | not reported | [0.63](/filings/0001034842-26-000032.md) | [3.28](/filings/0001034842-26-000052.md) | [1.46](/filings/0001104659-25-106268.md) | not reported | [0.44](/filings/0001034842-26-000032.md) | [0.88](/filings/0001034842-26-000052.md) |
| Basic EPS | $ per share | [(0.33)](/filings/0001558370-24-014862.md) | not reported | [(0.47)](/filings/0001558370-25-006493.md) | [(0.06)](/filings/0001558370-25-010281.md) | [0.71](/filings/0001104659-25-106268.md) | not reported | [0.64](/filings/0001034842-26-000032.md) | [3.33](/filings/0001034842-26-000052.md) | [1.55](/filings/0001104659-25-106268.md) | not reported | [0.47](/filings/0001034842-26-000032.md) | [0.93](/filings/0001034842-26-000052.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [45.4](/filings/0001558370-23-017987.md) | [32.8](/filings/0001558370-25-002169.md) | [25.6](/filings/0001558370-24-007041.md) | [36.1](/filings/0001558370-24-011079.md) | [51.7](/filings/0001558370-24-014862.md) | [56.7](/filings/0001034842-26-000015.md) | [45.7](/filings/0001558370-25-006493.md) | [53.4](/filings/0001558370-25-010281.md) | [48.5](/filings/0001104659-25-106268.md) | [40.6](/filings/0001034842-26-000052.md) | [24.4](/filings/0001034842-26-000032.md) | [60.8](/filings/0001034842-26-000052.md) |
| Current assets | $m | [95.0](/filings/0001558370-23-017987.md) | [99.3](/filings/0001558370-25-002169.md) | [92.5](/filings/0001558370-24-007041.md) | [94.7](/filings/0001558370-24-011079.md) | [106](/filings/0001558370-24-014862.md) | [135](/filings/0001034842-26-000015.md) | [147](/filings/0001558370-25-006493.md) | [175](/filings/0001558370-25-010281.md) | [215](/filings/0001104659-25-106268.md) | [240](/filings/0001034842-26-000052.md) | [234](/filings/0001034842-26-000032.md) | [186](/filings/0001034842-26-000052.md) |
| Total assets | $m | [115](/filings/0001558370-23-017987.md) | [117](/filings/0001558370-25-002169.md) | [127](/filings/0001558370-24-007041.md) | [128](/filings/0001558370-24-011079.md) | [139](/filings/0001558370-24-014862.md) | [164](/filings/0001034842-26-000015.md) | [176](/filings/0001558370-25-006493.md) | [207](/filings/0001558370-25-010281.md) | [243](/filings/0001104659-25-106268.md) | [514](/filings/0001034842-26-000052.md) | [505](/filings/0001034842-26-000032.md) | [521](/filings/0001034842-26-000052.md) |
| Current liabilities | $m | [48.3](/filings/0001558370-23-017987.md) | [53.3](/filings/0001558370-25-002169.md) | [73.2](/filings/0001558370-24-007041.md) | [58.6](/filings/0001558370-24-011079.md) | [54.3](/filings/0001558370-24-014862.md) | [63.3](/filings/0001034842-26-000015.md) | [66.6](/filings/0001558370-25-006493.md) | [86.6](/filings/0001558370-25-010281.md) | [94.4](/filings/0001104659-25-106268.md) | [99.2](/filings/0001034842-26-000052.md) | [89.5](/filings/0001034842-26-000032.md) | [95.6](/filings/0001034842-26-000052.md) |
| Total liabilities | $m | [147](/filings/0001558370-23-017987.md) | [146](/filings/0001558370-25-002169.md) | [158](/filings/0001558370-24-007041.md) | [158](/filings/0001558370-24-011079.md) | [154](/filings/0001558370-24-014862.md) | [161](/filings/0001034842-26-000015.md) | [157](/filings/0001558370-25-006493.md) | [125](/filings/0001558370-25-010281.md) | [125](/filings/0001104659-25-106268.md) | [122](/filings/0001034842-26-000052.md) | [105](/filings/0001034842-26-000032.md) | [95.6](/filings/0001034842-26-000052.md) |
| Long-term debt | $m | [60.0](/filings/0001558370-23-017987.md) | [60.0](/filings/0001558370-24-002475.md) | [60.0](/filings/0001558370-24-007041.md) | [60.0](/filings/0001558370-24-011079.md) | [60.0](/filings/0001558370-24-014862.md) | [60.0](/filings/0001558370-25-002169.md) | [60.0](/filings/0001558370-25-006493.md) | [60.0](/filings/0001558370-25-010281.md) | [60.0](/filings/0001104659-25-106268.md) | [52.5](/filings/0001034842-26-000015.md) | [45.0](/filings/0001034842-26-000032.md) | not reported |
| Shareholders' equity | $m | [(31.8)](/filings/0001558370-24-014862.md) | [(28.6)](/filings/0001034842-26-000015.md) | [(31.7)](/filings/0001104659-25-106268.md) | [(29.9)](/filings/0001104659-25-106268.md) | [(14.6)](/filings/0001104659-25-106268.md) | [3.3](/filings/0001034842-26-000052.md) | [18.6](/filings/0001034842-26-000052.md) | [81.9](/filings/0001034842-26-000052.md) | [118](/filings/0001104659-25-106268.md) | [391](/filings/0001034842-26-000052.md) | [400](/filings/0001034842-26-000052.md) | [425](/filings/0001034842-26-000052.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.4) d](/filings/0001558370-24-014862.md) | [(6.2) d](/filings/0001034842-26-000015.md) | [(5.0)](/filings/0001558370-25-006493.md) | [0.3 d](/filings/0001558370-25-010281.md) | [21.7 d](/filings/0001104659-25-106268.md) | [14.5 d](/filings/0001034842-26-000015.md) | [(0.9)](/filings/0001034842-26-000032.md) | [30.5 d](/filings/0001034842-26-000052.md) | [24.0 d](/filings/0001104659-25-106268.md) | [22.0 d](/filings/0001034842-26-000015.md) | [2.7](/filings/0001034842-26-000032.md) | [30.7 d](/filings/0001034842-26-000052.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001034842-26-000032.md) | [0.0 d](/filings/0001034842-26-000052.md) | not reported | not reported | [3.7](/filings/0001034842-26-000032.md) | [0.5 d](/filings/0001034842-26-000052.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [173](/filings/0001558370-23-017987.md) | [174](/filings/0001558370-24-007041.md) | [17.4](/filings/0001558370-24-011079.md) | [17.4](/filings/0001558370-24-014862.md) | [17.5](/filings/0001558370-25-006493.md) | [17.5](/filings/0001558370-25-010281.md) | [17.6](/filings/0001104659-25-106268.md) | [18.2](/filings/0001034842-26-000032.md) | [18.2](/filings/0001034842-26-000052.md) | [19.2](/filings/0001104659-25-106268.md) | [19.7](/filings/0001034842-26-000032.md) | [19.6](/filings/0001034842-26-000052.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 18,679,864 at 2026-07-30, from the cover of the [10-Q filed 2026-08-04](/filings/0001034842-26-000052.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.